Gramicidin D is a bactericidal antibiotic used in the treatment of dermatological and ophthalmic infections. Gramcidin D is a heterogeneous mixture of three antibiotic compounds, gramicidins A, B and C, making up 80%, 6%, and 14% respectively all of which are obtained from the soil bacterial species Bacillus brevis and...
- Mechanism
- Curator reviewed
Gramicidin D binds to and inserts itself into bacterial membranes (with a strong preference to gram-positive cell membranes). This results in membrane disruption and permeabilization (it acts as a channel). This leads to (i) loss of intracellular solutes (e.g., K+ and amino acids); (ii) dissipation of the transmembrane potential; (iii) inhibition of respiration; (iv) a reduction in ATP pools; and (v) inhibition of DNA, RNA, and protein synthesis, which leads to cell death.
- Primary indication
- For treatment of skin lesions, surface wounds and eye infections.Curator reviewed · 21 structured indications
- Formula / weight
- C96H135N19O16 · 1811.253 g/mol (avg)
- First approval
- Canada, 1996 · United States, 1955
- Also known as
- Bacillus brevis gramicidin D · Gramicidin · Gramicidin A · Gramicidin B · Gramicidin C
- Brand names
Resolves to
NDAYQJDHGXTBJL-MWWSRJDJSA-NSMILESCC(C)C[C@@H](NC(=O)CNC(=O)[C@@H](NC=O)C(C)C)C(=O)N[C@@H](C)C(=O)N[C@H](C(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@H](C(C)C)C(=O)N[C@@H](CC1=CNC2=C1C=CC=C2)C(=O)N[C@H](CC(C)C)C(=O)N[C@@H](CC1=CNC2=C1C=CC=C2)C(=O)N[C@H](CC(C)C)C(=O)N[C@@H](CC1=CNC2=C1C=CC=C2)C(=O)N[C@H](CC(C)C)C(=O)N[C@@H](CC1=CNC2=C1C=CC=C2)C(=O)NCCOWhat you can answer from here — as of August 31, 2026
Which drugs share a target with Gramicidin D, and which of those have an active Phase 3 trial?
Create a free account or log in to explore the full data card.
Create Account